#Mayo Clinic #Phenomix Sciences #obesity research

Phenomix Sciences and Mayo Clinic: A New Era in Obesity Medicine

In an exciting development set to be unveiled at the upcoming Digestive Disease Week (DDW) 2025, Phenomix Sciences, a pioneering force in precision obesity medicine, and the renowned Mayo Clinic will present a series of groundbreaking studies. Scheduled from May 4 to May 6 in San Diego, this event signals a significant leap forward in understanding and treating obesity as a complex, biologically influenced condition.

The research presentations encompass a total of 17 studies, eight of which incorporate Phenomix's innovative predictive machine learning algorithms. These findings promise to advance the field of obesity medicine, particularly in the areas of predicting responses to GLP-1 therapies, identifying new obesity sub-phenotypes, and refining decision-making for bariatric and endoscopic interventions.

Key Findings to be Revealed

Among the remarkable breakthroughs being shared are:

1. Predicting Side Effects from GLP-1 Therapies

Researchers will disclose new genetic risk scores (GRS) that can identify patients likely to experience adverse effects like nausea when undergoing GLP-1 treatment. These insights utilize the MyPhenome® test, enhancing the precision in medication matching for better patient outcomes and improving the design of clinical trials for anti-obesity medications (AOMs).

2. Identifying a New Obesity Sub-Phenotype

In a prestigious plenary session, a newly recognized obesity sub-phenotype, characterized by rapid gastric emptying (dubbed the